Is Canafenib a hormonal drug? What is the mechanism of action?

Encorafenib is not a hormonal drug, but a targeted therapy drug, which is a BRAF kinase inhibitor and is specifically used to treat cancer patients with BRAF V600E mutations. BRAF is an important kinase involved in cell proliferation and survival. In certain tumors (such as melanoma, colorectal cancer, and non-small cell lung cancer (NSCLC)), the V600E mutation of the BRAF gene can lead to abnormal activation of the MAPK signaling pathway, causing tumor cells to continue to proliferate uncontrollably. Canafenib achieves anti-cancer effects by highly selectively inhibiting mutant BRAF protein and blocking abnormal signaling, thereby inhibiting the proliferation and survival of tumor cells.

Different from traditional chemotherapy, canafenib is a precision treatment drug and is mainly used for patients who have been confirmed to carry the BRAF V600E mutation through genetic testing. It does not kill tumors by destroying normal cells, but targets abnormally activated molecular targets in tumor cells, so side effects are usually relatively more controllable. It is worth mentioning that in some cancer types, canafenib alone is prone to resistance due to EGFR feedback activation, so it is often used in combination with EGFR inhibitors such as cetuximab to enhance efficacy and prolong progression-free survival (PFS).

To sum up, canafenib is not a hormonal drug, but a molecularly targeted drug. Its anti-cancer mechanism is based on precise molecular target inhibition. It mainly acts on tumors driven by BRAF mutations. It is one of the important drugs in the current field of targeted tumor therapy and an important part of the current precision tumor treatment. It is recommended that patients undergo BRAF gene testing before use to ensure the suitability and efficacy of the drug. With the development of precision medicine, canafenib is providing new treatment hope for more cancer patients.

Reference materials:https://www.braftovi.com/